T1	Participants 79 107	metastatic colorectal cancer
T2	Participants 225 274	patients with metastatic colorectal cancer (mCRC)
T3	Participants 446 674	A selection of 17 polymorphisms in genes encoding drug targets, pathway molecules and detoxification enzymes was analyzed in 279 previously untreated mCRC patients treated with capecitabine, oxaliplatin and bevacizumab (CAPOX-B)
T4	Participants 1469 1482	mCRC patients
